Genetics of glucocorticoids in asthma

New England Journal of Medicine

Volumn 365, Issue 25, 2011, Pages 2434-2436

  Van Den Berge, Maarten ^a   Hiemstra, Pieter S ^b   Postma, Dirkje S ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; GLUCOCORTICOID; SALMETEROL; GLUCOCORTICOID RECEPTOR;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; GENE PRODUCT; GENETIC VARIABILITY; GENOTYPE; GLCCI1 GENE; HUMAN; LETTER; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RESIDUAL VOLUME; TREATMENT DURATION; TREATMENT RESPONSE; FEMALE; GENETICS; MALE; NOTE; SINGLE NUCLEOTIDE POLYMORPHISM;

ASTHMA; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, GLUCOCORTICOID;

EID: 84855179239     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1112547     Document Type: Letter

References (2)

1. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011;365:1173-83.
2. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151:517-27.